BACKGROUND AND OBJECTIVES: Anemia in patients with CKD is highly related to impaired erythropoietin (EPO) response, the timing and determinants of which remain unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study measured EPO levels and studied their relation to GFR measured by 51Cr-EDTA renal clearance (mGFR) in 336 all-stage CKD patients not receiving any erythropoiesis-stimulating agent. RESULTS: In patients with anemia defined by World Health Organization criteria (hemoglobin [Hb] <13 g/dl in men and 12 g/dl in women), EPO response to Hb level varied by mGFR level. EPO and Hb levels were negatively correlated (r=-0.22, P=0.04) when mGFR was >30 ml/min per 1.73 m(2), whereas they were not correlated when mGFR was <30 (r=0.09, P=0.3; P for interaction=0.01). In patients with anemia, the ratio of observed EPO to the level predicted by the equation for their Hb level decreased from 0.72 (interquartile range, 0.57-0.95) for mGFR ≥60 ml/min per 1.73 m(2) to 0.36 (interquartile range, 0.16-0.69) for mGFR <15. Obesity, diabetes with nephropathy other than diabetic glomerulopathy, absolute iron deficiency, and high C-reactive protein concentrations were associated with increased EPO levels, independent of Hb and mGFR. CONCLUSIONS: Anemia in CKD is marked by an early relative EPO deficiency, but several factors besides Hb may persistently stimulate EPO synthesis. Although EPO deficiency is likely the main determinant of anemia in patients with advanced CKD, the presence of anemia in those with mGFR >30 ml/min per 1.73 m(2) calls for other explanatory factors.
BACKGROUND AND OBJECTIVES:Anemia in patients with CKD is highly related to impaired erythropoietin (EPO) response, the timing and determinants of which remain unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This study measured EPO levels and studied their relation to GFR measured by 51Cr-EDTA renal clearance (mGFR) in 336 all-stage CKD patients not receiving any erythropoiesis-stimulating agent. RESULTS: In patients with anemia defined by World Health Organization criteria (hemoglobin [Hb] <13 g/dl in men and 12 g/dl in women), EPO response to Hb level varied by mGFR level. EPO and Hb levels were negatively correlated (r=-0.22, P=0.04) when mGFR was >30 ml/min per 1.73 m(2), whereas they were not correlated when mGFR was <30 (r=0.09, P=0.3; P for interaction=0.01). In patients with anemia, the ratio of observed EPO to the level predicted by the equation for their Hb level decreased from 0.72 (interquartile range, 0.57-0.95) for mGFR ≥60 ml/min per 1.73 m(2) to 0.36 (interquartile range, 0.16-0.69) for mGFR <15. Obesity, diabetes with nephropathy other than diabetic glomerulopathy, absolute iron deficiency, and high C-reactive protein concentrations were associated with increased EPO levels, independent of Hb and mGFR. CONCLUSIONS:Anemia in CKD is marked by an early relative EPO deficiency, but several factors besides Hb may persistently stimulate EPO synthesis. Although EPO deficiency is likely the main determinant of anemia in patients with advanced CKD, the presence of anemia in those with mGFR >30 ml/min per 1.73 m(2) calls for other explanatory factors.
Authors: Scott D Solomon; Hajime Uno; Eldrin F Lewis; Kai-Uwe Eckardt; Julie Lin; Emmanuel A Burdmann; Dick de Zeeuw; Peter Ivanovich; Andrew S Levey; Patrick Parfrey; Giuseppe Remuzzi; Ajay K Singh; Robert Toto; Fannie Huang; Jerome Rossert; John J V McMurray; Marc A Pfeffer Journal: N Engl J Med Date: 2010-09-16 Impact factor: 91.245
Authors: Grant C Bullock; Lorrie L Delehanty; Anne-Laure Talbot; Sara L Gonias; Wing-Hang Tong; Tracey A Rouault; Brian Dewar; Jeffrey M Macdonald; Jason J Chruma; Adam N Goldfarb Journal: Blood Date: 2010-04-20 Impact factor: 22.113
Authors: Surjit K Srai; Bomee Chung; Joanne Marks; Katayoun Pourvali; Nita Solanky; Chiara Rapisarda; Timothy B Chaston; Rumeza Hanif; Robert J Unwin; Edward S Debnam; Paul A Sharp Journal: Kidney Int Date: 2010-07-14 Impact factor: 10.612
Authors: Thomas Fehr; Peter Ammann; Daniela Garzoni; Wolfgang Korte; Walter Fierz; Hans Rickli; Rudolf P Wüthrich Journal: Kidney Int Date: 2004-09 Impact factor: 10.612
Authors: Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto Journal: N Engl J Med Date: 2009-10-30 Impact factor: 91.245
Authors: Sophie de Seigneux; Anne-Kristine Meinild Lundby; Lena Berchtold; Anders H Berg; Patrick Saudan; Carsten Lundby Journal: J Am Soc Nephrol Date: 2016-01-12 Impact factor: 10.121
Authors: Steven Fishbane; Simon D Roger; Edouard Martin; Grant Runyan; Janet O'Neil; Ping Qiu; Francesco Locatelli Journal: Clin J Am Soc Nephrol Date: 2012-12-14 Impact factor: 8.237
Authors: Giorgina B Piccoli; Giorgio Grassi; Gianfranca Cabiddu; Marta Nazha; Simona Roggero; Irene Capizzi; Agostino De Pascale; Adriano M Priola; Cristina Di Vico; Stefania Maxia; Valentina Loi; Anna M Asunis; Antonello Pani; Andrea Veltri Journal: Rev Diabet Stud Date: 2015-08-10
Authors: Lucile Mercadal; Marie Metzger; Jean Philippe Haymann; Eric Thervet; Jean-Jacques Boffa; Martin Flamant; François Vrtovsnik; Cédric Gauci; Marc Froissart; Bénédicte Stengel Journal: PLoS One Date: 2014-02-19 Impact factor: 3.240
Authors: Shin Young Ahn; Jiwon Ryu; Seon Ha Baek; Sejoong Kim; Ki Young Na; Ki Woong Kim; Dong-Wan Chae; Ho Jun Chin Journal: PLoS One Date: 2013-12-18 Impact factor: 3.240
Authors: Lucile Mercadal; Lucile Mercadel; Marie Metzger; Jean Philippe Haymann; Eric Thervet; Jean-Jacques Boffa; Martin Flamant; François Vrtovsnik; Pascal Houillier; Marc Froissart; Bénédicte Stengel Journal: PLoS One Date: 2014-06-30 Impact factor: 3.240